Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P42345 (
mTOR
)
26,049
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The
dedicator of cytokinesis 5
(
DOCK5
) is associated with obesity. However, the mechanism by which
DOCK5
contributes to obesity remains completely unknown. Here, we show that hepatic
DOCK5
expression significantly decreases at a state of insulin resistance (IR). Deletion of
DOCK5
in mice reduces energy expenditure, promotes obesity, augments IR, dysregulates glucose metabolism, and activates the
mTOR
(Raptor)/S6K1 pathway under a high-fat diet (HFD). The overexpression of
DOCK5
in hepatocytes inhibits gluconeogenic gene expression and increases the level of insulin receptor (InsR) and Akt phosphorylation.
DOCK5
overexpression also inhibits
mTOR
/S6K1 phosphorylation and decreases the level of raptor protein expression. The opposite effects were observed in
DOCK5
-deficient hepatocytes. Importantly, in liver-specific Raptor knockout mice and associated hepatocytes, the effects of an adeno-associated virus (AAV8)- or adenovirus-mediated
DOCK5
knockdown on glucose metabolism and insulin signaling are largely eliminated. Additionally,
DOCK5
-Raptor interaction is indispensable for the
DOCK5
-mediated regulation of hepatic glucose production (HGP). Therefore,
DOCK5
acts as a regulator of Raptor to control hepatic insulin activity and glucose homeostasis.
...
PMID:DOCK5 regulates energy balance and hepatic insulin sensitivity by targeting mTORC1 signaling. 3188 14